The reno-protective effects, in particular, have been very conclusive in studies such as DAPA-CKD (47) and Credence (48) that the new paradigms of treatment of DKD have advanced SGLT-2 blockers to the first line of therapy. This evidence concerns the gene SLC5A2 and diabetic kidney disease.